Disruptive APDS technology for the treatment of dysglycaemia
Brittle diabetes is a special form that affects one in three out of every 1,000 insulin-dependent patients. Recurrent episodes of DKA and the resulting hospitalisation reduce the quality of life of these people enormously. Conventional diabetes treatments often do not achieve the desired results. A new innovative approach with a disruptive technology now promises to optimise the regulation of blood glucose levels and increase the time-in-range, which should improve the course of the disease and the quality of life of those affected and reduce constant hospital stays. See for yourself!
Field of expertise
Your request to us
We connect people with opportunities and knowledge
We are here for you! Whether project inquiries, market information or the desire for an active cooperation. We have a sympathetic ear for your concerns and are sure we can help quickly.
